ELUT vs. PASG, GNTA, CGTX, TIL, GRTS, DTIL, IKNA, ATRA, CDTX, and TSBX
Should you be buying Elutia stock or one of its competitors? The main competitors of Elutia include Passage Bio (PASG), Genenta Science (GNTA), Cognition Therapeutics (CGTX), Instil Bio (TIL), Gritstone bio (GRTS), Precision BioSciences (DTIL), Ikena Oncology (IKNA), Atara Biotherapeutics (ATRA), Cidara Therapeutics (CDTX), and Turnstone Biologics (TSBX). These companies are all part of the "biological products, except diagnostic" industry.
Passage Bio (NASDAQ:PASG) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, community ranking, dividends and earnings.
Elutia has higher revenue and earnings than Passage Bio. Elutia is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.
Passage Bio presently has a consensus price target of $9.33, indicating a potential upside of 607.07%. Elutia has a consensus price target of $6.00, indicating a potential upside of 115.83%. Given Elutia's higher possible upside, analysts plainly believe Passage Bio is more favorable than Elutia.
Passage Bio has a net margin of 0.00% compared to Passage Bio's net margin of -106.54%. Passage Bio's return on equity of 0.00% beat Elutia's return on equity.
Passage Bio received 43 more outperform votes than Elutia when rated by MarketBeat users. However, 100.00% of users gave Elutia an outperform vote while only 66.20% of users gave Passage Bio an outperform vote.
Passage Bio has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Elutia has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.
53.5% of Passage Bio shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 4.3% of Passage Bio shares are held by company insiders. Comparatively, 37.1% of Elutia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Passage Bio had 2 more articles in the media than Elutia. MarketBeat recorded 4 mentions for Passage Bio and 2 mentions for Elutia. Elutia's average media sentiment score of 0.09 beat Passage Bio's score of -0.33 indicating that Passage Bio is being referred to more favorably in the media.
Summary
Passage Bio beats Elutia on 10 of the 16 factors compared between the two stocks.
Get Elutia News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELUT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
